Zebrafish with parts of nervous system in green.
Oust the Mouse: A Plan to Reduce Mammal Use in Drug Development
The Scientist spoke to Mount Desert Island Biological Laboratory’s Jim Strickland about the institute’s new MDI Bioscience initiative to perform more drug testing and development in nonmammalian models.
ABOVE: Marko Pende, Science Advances
Oust the Mouse: A Plan to Reduce Mammal Use in Drug Development
Oust the Mouse: A Plan to Reduce Mammal Use in Drug Development

The Scientist spoke to Mount Desert Island Biological Laboratory’s Jim Strickland about the institute’s new MDI Bioscience initiative to perform more drug testing and development in nonmammalian models.

The Scientist spoke to Mount Desert Island Biological Laboratory’s Jim Strickland about the institute’s new MDI Bioscience initiative to perform more drug testing and development in nonmammalian models.

ABOVE: Marko Pende, Science Advances

pharmaceutical industry

An orange CRISPR Cas 9 enzyme cutting DNA
CRISPR-Based Treatment Successfully Lowers Toxic Protein Levels
Natalia Mesa | Mar 2, 2022
A first-of-its-kind gene therapy dramatically reduced misfolded protein levels in some clinical trial participants for up to six months and reduced levels in all participants for up to a year.
hundred dollar bills with stethoscope on top
Most Medical Papers Didn’t Disclose Industry Payments: Preprint
Natalia Mesa | Jan 24, 2022
Authors of papers published in JAMA and NEJM received millions in undisclosed payments in 2017, an analysis finds.
blue and white building sign
Biden Picks Robert Califf to Head the FDA for a Second Time
Chloe Tenn | Nov 12, 2021
The cardiologist was briefly the FDA Commissioner in the Obama Administration, and now has a second chance to act on plans he tried to implement during his first tenure.
Updated
Merck research facility in San Francisco
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Chloe Tenn | Oct 1, 2021
Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.
José Baselga, cancer, research, oncology, AstraZeneca, breast cancer, drugs, therapeutics, obituary, dies
José Baselga, Renowned Oncologist, Dies at 61
Asher Jones | Mar 22, 2021
The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.
Biopharma Looks to the Netherlands as European Hub
Jef Akst | Feb 1, 2021
The recent move of the European Medicines Agency from London to Amsterdam is a reflection of the city’s vibrant life sciences and health sector and supporting industries.
Pharma Looks to Outer Space to Boost Drug R&D
Katarina Zimmer | Dec 1, 2020
There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
COVID-19, SARS-CoV-2, coronavirus, pandemic, transmission, superspread, genome, virus, tracking, Biogen, Massachusetts
Thousands of Coronavirus Infections Stemmed from a Biotech Event
Amanda Heidt | Aug 26, 2020
Officials had initially linked 97 cases to a single conference held by Biogen in February in Boston, but a new study tracking viral genomes suggests the number may be as high as 20,000.
Gilead Urged to Explore Remdesivir Relative as COVID-19 Drug
Catherine Offord | Aug 11, 2020
Citizen advocates push the pharmaceutical company to examine a compound that has been used to treat certain coronavirus infections in cats.
Activities Discovered for Some Inactive Drug Ingredients
Ruth Williams | Jul 23, 2020
Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.
How the Pharma Industry Pulled Off the Pivot to COVID-19
Diana Kwon | Jul 13, 2020
The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.
an illustration showing amyloid plaques around brain cells
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Shawna Williams | Dec 6, 2019
The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.
Former FDA Commissioner Frank Young Dies
Jef Akst | Dec 2, 2019
The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Emily Makowski | Nov 25, 2019
The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.
Pharma’s Ghost Labs Find New Life
Katarina Zimmer | Nov 1, 2019
Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
Catherine Offord | Oct 14, 2019
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
cryopreservation facility
Immune Cell Bank Bets on Future CAR T Success
Nicoletta Lanese | Aug 16, 2019
The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.
gene therapy approval used manipulated data
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Nicoletta Lanese | Aug 7, 2019
The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.